What is AMGN revenue?

Amgen Inc. (AMGN) reported $38.90B of revenue for the twelve months ended Sep 30, 2026. That is up 8.2% from the year before. Revenue for fiscal 2025 was $36.75B.

Yes. Amgen Inc. earned $9.39B in net income for the twelve months ended Sep 30, 2026, a net margin of 24.1%.

How much cash and debt does AMGN have?

Amgen Inc. reported $13.19B in cash and cash equivalents and $54.01B of debt on its most recent balance sheet in SEC filings.

How fast is AMGN revenue growing?

Amgen Inc.'s revenue changed +10.0% in fiscal 2025, to $36.75B. Its compound annual growth rate was +7.6% over 5 years and +5.4% over 10 years.

What is AMGN gross margin?

Amgen Inc.'s gross profit was $27.58B on $38.90B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 70.9%.

What is AMGN free cash flow?

Amgen Inc. generated $9.58B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $12.04B less capital expenditures.

What is AMGN earnings per share?

Diluted earnings per share were $17.24 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did AMGN last report financial results?

The latest statements here come from Amgen Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.

Where does this AMGN financial data come from?

Quantisnow builds these statements from the structured XBRL data Amgen Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · AMGN

Amgen Inc. (AMGN) financials

For the twelve months ended Sep 30, 2026, Amgen Inc. reported $38.90B of revenue and $9.39B of net income.

Revenue, TTM: $38.90B
Revenue growth, YoY: +8.2%
Net income, TTM: $9.39B
Net income growth, YoY: +34.1%
Net margin: 24.1%
Free cash flow, TTM: $9.58B
EPS, diluted, TTM: $17.24
EPS growth, YoY: +33.1%
Cash: $13.19B
Total debt: $54.01B
P/E: 26.52
P/S: 6.40
Market cap: $249.05B

Annual revenue$36.75B

FY2016FY2025

Annual net income$7.71B

FY2016FY2025

Annual free cash flow$8.10B

FY2016FY2025

AMGN revenue and earnings growth

AMGN revenueQ3 2026$10.37B

Quarter YoY: +8.5%
QoQ: +3.1%
FY YoY: +10.0%
5Y CAGR: +7.6%
10Y CAGR: +5.4%

AMGN revenue was $10.37B in fiscal Q3 2026 (ended Sep 30, 2026), up 8.5% from a year earlier and up 3.1% from the prior quarter. For the full fiscal 2025 it was $36.75B, up 10.0% from fiscal 2024. Compound annual growth was +7.6% over 5 years and +5.4% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

AMGN net incomeQ3 2026$3.86B

Quarter YoY: +20.1%
QoQ: +62.7%
FY YoY: +88.5%
5Y CAGR: +1.2%
10Y CAGR: +1.1%

AMGN net income was $3.86B in fiscal Q3 2026 (ended Sep 30, 2026), up 20.1% from a year earlier and up 62.7% from the prior quarter. For the full fiscal 2025 it was $7.71B, up 88.5% from fiscal 2024. Compound annual growth was +1.2% over 5 years and +1.1% over 10 years. It rose in 5 of the last 10 fiscal years.

AMGN EPSQ3 2026$7.08

Quarter YoY: +19.4%
QoQ: +62.0%
FY YoY: +88.2%
5Y CAGR: +2.9%
10Y CAGR: +4.6%

AMGN diluted EPS was $7.08 in fiscal Q3 2026 (ended Sep 30, 2026), up 19.4% from a year earlier and up 62.0% from the prior quarter. For the full fiscal 2025 it was $14.23, up 88.2% from fiscal 2024. Compound annual growth was +2.9% over 5 years and +4.6% over 10 years.

AMGN free cash flowQ3 2026$3.65B

Quarter YoY: -14.0%
QoQ: +4.7%
FY YoY: -22.1%
5Y CAGR: -3.9%
10Y CAGR: -1.2%

AMGN free cash flow was $3.65B in fiscal Q3 2026 (ended Sep 30, 2026), down 14.0% from a year earlier and up 4.7% from the prior quarter. For the full fiscal 2025 it was $8.10B, down 22.1% from fiscal 2024. Compound annual growth was -3.9% over 5 years and -1.2% over 10 years. It rose in 6 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$36.75B	$33.42B	$28.19B	$26.32B	$25.98B	$25.42B	$23.36B	$23.75B	$22.85B	$22.99B
Cost of revenue	$12.04B	$12.86B	$8.45B	$6.41B	$6.45B	$6.16B	$4.36B	$4.10B	$4.07B	$4.16B
Gross profit	$24.71B	$20.57B	$19.74B	$19.92B	$19.52B	$19.27B	$19.01B	$19.65B	$18.78B	$18.83B
Research and development	$7.27B	$5.96B	$4.78B	$4.43B	$4.82B	$4.21B	$4.12B	$3.74B	$3.56B	$3.84B
Selling, general and admin	$7.05B	$7.10B	$6.18B	$5.41B	$5.37B	$5.73B	$5.15B	$5.33B	$4.87B	$5.06B
Operating income	$9.08B	$7.26B	$7.90B	$9.57B	$7.64B	$9.14B	$9.67B	$10.26B	$9.97B	$9.79B
Pre-tax income	$8.98B	$4.61B	$7.86B	$7.35B	$6.70B	$8.13B	$9.14B	$9.54B	$9.60B	$9.16B
Income tax	$1.26B	$519.00M	$1.14B	$794.00M	$808.00M	$869.00M	$1.30B	$1.15B	$7.62B	$1.44B
Net income	$7.71B	$4.09B	$6.72B	$6.55B	$5.89B	$7.26B	$7.84B	$8.39B	$1.98B	$7.72B
EPS, basic	$14.33	$7.62	$12.56	$12.18	$10.34	$12.40	$12.96	$12.70	$2.71	$10.32
EPS, diluted	$14.23	$7.56	$12.49	$12.11	$10.28	$12.31	$12.88	$12.62	$2.69	$10.24
Diluted shares	542.0M	541.0M	538.0M	541.0M	573.0M	590.0M	609.0M	665.0M	735.0M	754.0M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$9.13B	$11.97B	$10.94B	$7.63B	$7.99B	$6.27B	$6.04B	$6.95B	$3.80B	$3.24B
Receivables	$9.57B	$6.78B	$7.27B	$5.56B	$4.89B	$4.53B	$4.06B	$3.58B	$3.24B	$3.17B
Inventory	$6.22B	$7.00B	$9.52B	$4.93B	$4.09B	$3.89B	$3.58B	$2.94B	$2.83B	$2.75B
Current assets	$29.06B	$29.03B	$30.33B	$22.19B	$19.39B	$21.14B	$18.44B	$37.62B	$49.48B	$46.01B
Goodwill	$18.68B	$18.64B	$18.63B	$15.53B	$14.89B	$14.69B	$14.70B	$14.70B	$14.76B	$14.76B
Total assets	$90.59B	$91.84B	$97.15B	$65.12B	$61.16B	$62.95B	$59.71B	$66.42B	$79.95B	$77.63B
Current liabilities	$25.49B	$23.10B	$18.39B	$15.69B	$12.18B	$11.65B	$12.84B	$13.49B	$9.02B	$11.20B
Short-term debt	$4.60B	$3.55B	$1.44B	$1.59B	$87.00M	$91.00M	$2.95B	$4.42B	$1.15B	$4.40B
Long-term debt	$50.01B	$56.55B	$63.17B	$37.35B	$33.22B	$32.90B	$26.95B	$29.51B	$34.19B	$30.19B
Total debt	$54.60B	$60.10B	$64.61B	$38.95B	$33.31B	$32.99B	$29.90B	$33.93B	$35.34B	$34.60B
Shareholders' equity	$8.66B	$5.88B	$6.23B	$3.66B	$6.70B	$9.41B	$9.67B	$12.50B	$25.24B	$29.88B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$9.96B	$11.49B	$8.47B	$9.72B	$9.26B	$10.50B	$9.15B	$11.30B	$11.18B	$10.35B
Capital expenditures	$1.86B	$1.10B	$1.11B	$936.00M	$880.00M	$608.00M	$618.00M	$738.00M	$664.00M	$738.00M
Free cash flow	$8.10B	$10.39B	$7.36B	$8.79B	$8.38B	$9.89B	$8.53B	$10.56B	$10.51B	$9.62B
Investing cash flow	-$1.94B	-$1.05B	-$26.20B	-$6.04B	$733.00M	-$5.40B	$5.71B	$14.34B	-$4.02B	-$8.66B
Financing cash flow	-$10.86B	-$9.41B	$21.05B	-$4.04B	-$8.27B	-$4.87B	-$15.77B	-$22.49B	-$6.59B	-$2.60B
Dividends paid	$5.12B	$4.83B	$4.56B	$4.20B	$4.01B	$3.75B	$3.51B	$3.51B	$3.37B	$3.00B
Share repurchases	$0	$200.00M	$0	$6.36B	$4.97B	$3.49B	$7.70B	$17.79B	$3.16B	$2.96B
Stock-based compensation	$494.00M	$530.00M	$431.00M	$401.00M	$341.00M	$330.00M	$308.00M	$311.00M	$329.00M	$311.00M
Depreciation and amortization	$5.17B	$5.59B	$4.07B	$3.42B	$3.40B	$3.60B	$2.21B	$1.95B	$1.96B	$2.10B

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	10.0%	18.6%	7.1%	1.3%	2.2%	8.8%	-1.6%	3.9%	-0.6%	6.1%
Net income growth, YoY	88.5%	-39.1%	2.5%	11.2%	-18.9%	-7.4%	-6.6%	324.2%	-74.4%	11.3%
EPS growth, YoY	88.2%	-39.5%	3.1%	17.8%	-16.5%	-4.4%	2.1%	369.1%	-73.7%	13.0%
Gross margin	67.2%	61.5%	70.0%	75.7%	75.2%	75.8%	81.4%	82.7%	82.2%	81.9%
Operating margin	24.7%	21.7%	28.0%	36.3%	29.4%	35.9%	41.4%	43.2%	43.6%	42.6%
Net margin	21.0%	12.2%	23.8%	24.9%	22.7%	28.6%	33.6%	35.3%	8.7%	33.6%
Free cash flow margin	22.0%	31.1%	26.1%	33.4%	32.3%	38.9%	36.5%	44.5%	46.0%	41.8%
Return on equity	89.1%	69.6%	107.8%	179.0%	88.0%	77.2%	81.1%	67.2%	7.8%	25.8%
Return on assets	8.5%	4.5%	6.9%	10.1%	9.6%	11.5%	13.1%	12.6%	2.5%	9.9%
Current ratio	1.14	1.26	1.65	1.41	1.59	1.81	1.44	2.79	5.49	4.11
Debt to equity	6.31	10.23	10.37	10.64	4.97	3.51	3.09	2.71	1.40	1.16

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$10.37B	$10.05B	$8.62B	$9.87B	$9.56B	$9.18B	$8.15B	$9.09B	$8.50B	$8.39B	$7.45B	$8.20B
Cost of revenue	$2.79B	$2.81B	$2.74B	$2.98B	$3.08B	$3.01B	$2.97B	$3.11B	$3.31B	$3.24B	$3.20B	$3.11B
Gross profit	$7.58B	$7.24B	$5.87B	$6.89B	$6.47B	$6.17B	$5.18B	$5.97B	$5.19B	$5.15B	$4.25B	$5.08B
Research and development	$2.11B	$1.87B	$1.72B	$2.14B	$1.90B	$1.74B	$1.49B	$1.72B	$1.45B	$1.45B	$1.34B	$1.53B
Selling, general and admin	$1.68B	$1.75B	$1.60B	$1.95B	$1.72B	$1.69B	$1.69B	$1.88B	$1.63B	$1.78B	$1.81B	$2.27B
Operating income	$3.71B	$3.51B	$2.67B	$2.72B	$2.53B	$2.66B	$1.18B	$2.31B	$2.05B	$1.91B	$991.00M	$1.27B
Pre-tax income	$4.69B	$2.77B	$2.08B	$1.51B	$3.92B	$1.57B	$1.97B	$782.00M	$3.10B	$794.00M	-$68.00M	$852.00M
Income tax	$822.00M	$393.00M	$265.00M	$181.00M	$705.00M	$136.00M	$243.00M	$155.00M	$271.00M	$48.00M	$45.00M	$85.00M
Net income	$3.86B	$2.38B	$1.82B	$1.33B	$3.22B	$1.43B	$1.73B	$627.00M	$2.83B	$746.00M	-$113.00M	$767.00M
EPS, basic	$7.14	$4.40	$3.37	$2.47	$5.98	$2.66	$3.22	$1.17	$5.27	$1.39	-$0.21	$1.43
EPS, diluted	$7.08	$4.37	$3.34	$2.45	$5.93	$2.65	$3.20	$1.17	$5.22	$1.38	-$0.21	$1.42
Diluted shares	546.0M	544.0M	544.0M	-	542.0M	541.0M	541.0M	-	542.0M	541.0M	536.0M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$13.19B	$13.99B	$12.04B	$9.13B	$9.45B	$8.03B	$8.81B	$11.97B	$9.01B	$9.30B	$9.71B	$10.94B
Receivables	$10.35B	$10.23B	$9.14B	$9.57B	$8.49B	$8.70B	$8.13B	$6.78B	$7.32B	$6.93B	$6.78B	$7.27B
Inventory	$6.39B	$6.22B	$6.19B	$6.22B	$6.35B	$6.58B	$6.73B	$7.00B	$7.36B	$8.00B	$8.72B	$9.52B
Current assets	$34.36B	$34.96B	$31.48B	$29.06B	$27.89B	$26.73B	$26.93B	$29.03B	$26.77B	$27.21B	$28.03B	$30.33B
Goodwill	$18.66B	$18.67B	$18.67B	$18.68B	$18.68B	$18.67B	$18.64B	$18.64B	$18.66B	$18.62B	$18.57B	$18.63B
Total assets	$96.05B	$95.64B	$92.50B	$90.59B	$90.14B	$87.90B	$89.37B	$91.84B	$90.88B	$90.91B	$92.98B	$97.15B
Current liabilities	$23.23B	$25.50B	$24.95B	$25.49B	$21.79B	$20.48B	$23.01B	$23.10B	$20.31B	$21.52B	$19.71B	$18.39B
Short-term debt	$2.40B	$5.45B	$5.44B	$4.60B	$2.15B	$2.44B	$3.37B	$3.55B	$3.54B	$5.53B	$3.96B	$1.44B
Long-term debt	$51.61B	$51.86B	$51.89B	$50.01B	$52.43B	$53.76B	$54.01B	$56.55B	$56.85B	$57.12B	$60.06B	$63.17B
Total debt	$54.01B	$57.30B	$57.32B	$54.60B	$54.59B	$56.20B	$57.38B	$60.10B	$60.40B	$62.65B	$64.02B	$64.61B
Shareholders' equity	$14.35B	$11.69B	$9.19B	$8.66B	$9.62B	$7.43B	$6.21B	$5.88B	$7.53B	$5.92B	$5.02B	$6.23B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$4.24B	$4.00B	$2.19B	$1.60B	$4.68B	$2.28B	$1.39B	$4.77B	$3.57B	$2.46B	$689.00M	$538.00M
Capital expenditures	$587.00M	$513.00M	$712.00M	$642.00M	$436.00M	$369.00M	$411.00M	$371.00M	$257.00M	$238.00M	$230.00M	$249.00M
Free cash flow	$3.65B	$3.49B	$1.48B	$961.00M	$4.25B	$1.91B	$980.00M	$4.40B	$3.31B	$2.22B	$459.00M	$289.00M
Investing cash flow	-$649.00M	-$569.00M	-$716.00M	-$693.00M	-$414.00M	-$389.00M	-$447.00M	-$402.00M	-$210.00M	-$217.00M	-$217.00M	-$27.09B
Financing cash flow	-$4.39B	-$1.48B	$1.44B	-$1.23B	-$2.85B	-$2.67B	-$4.11B	-$1.41B	-$3.65B	-$2.65B	-$1.71B	$2.75B
Dividends paid	$1.36B	$1.36B	$1.36B	$1.28B	$1.28B	$1.28B	$1.28B	$1.21B	$1.21B	$1.21B	$1.21B	$1.14B
Share repurchases	-	-	-	-	-	-	-	-	-	-	-	$0
Stock-based compensation	$128.00M	$165.00M	$75.00M	$125.00M	$127.00M	$157.00M	$85.00M	$134.00M	$136.00M	$157.00M	$103.00M	$161.00M
Depreciation and amortization	$233.00M	$222.00M	$1.12B	$1.13B	$232.00M	$220.00M	$1.39B	$1.40B	$198.00M	$202.00M	$1.40B	$1.38B

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	8.5%	9.5%	5.8%	8.6%	12.4%	9.4%	9.4%	10.9%	23.2%	20.1%	22.0%	19.8%
Net income growth, YoY	20.1%	65.9%	5.1%	112.6%	13.6%	92.0%	-	-18.3%	63.6%	-45.9%	-	-52.5%
EPS growth, YoY	19.4%	64.9%	4.4%	109.4%	13.6%	92.0%	-	-17.6%	62.1%	-46.3%	-	-52.7%
Gross margin	73.1%	72.0%	68.2%	69.8%	67.8%	67.2%	63.6%	65.7%	61.1%	61.4%	57.0%	62.0%
Operating margin	35.8%	35.0%	30.9%	27.6%	26.4%	28.9%	14.5%	25.4%	24.1%	22.8%	13.3%	15.5%
Net margin	37.3%	23.6%	21.1%	13.5%	33.7%	15.6%	21.2%	6.9%	33.3%	8.9%	-1.5%	9.4%
Free cash flow margin	35.3%	34.7%	17.1%	9.7%	44.4%	20.8%	12.0%	48.4%	39.0%	26.5%	6.2%	3.5%
Current ratio	1.48	1.37	1.26	1.14	1.28	1.31	1.17	1.26	1.32	1.26	1.42	1.65
Debt to equity	3.76	4.90	6.24	6.31	5.67	7.57	9.24	10.23	8.02	10.57	12.75	10.37

Source: XBRL data Amgen Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

AMGN peers

Company	Revenue	Growth	Net income	Net margin	Market cap
AMGN	$38.90B	+8.2%	$9.39B	24.1%	$249.05B
ABBVAbbVie Inc.	$66.01B	+10.7%	$10.34B	15.7%	$514.92B
MRKMerck & Company Inc.	$67.38B	+4.9%	$2.45B	3.6%	$361.71B
NVSNovartis AG	$54.53B	+8.4%	$13.98B	25.6%	$310.17B
AZNAstraZeneca PLC	$58.74B	+8.6%	$10.22B	17.4%	$289.10B
PFEPfizer Inc.	$63.63B	+1.3%	$4.03B	6.3%	$167.49B
BMYBristol-Myers Squibb Company	$50.03B	+4.2%	$9.24B	18.5%	$127.01B
SNYSanofi	€43.63B	+6.2%	€7.81B	17.9%	$114.71B
TAKTakeda Pharmaceutical Company Limited	¥4.51T	-1.7%	-¥152.39B	-3.4%	$66.40B

AMGN FAQ

9 questions

What is AMGN revenue?
Amgen Inc. (AMGN) reported $38.90B of revenue for the twelve months ended Sep 30, 2026. That is up 8.2% from the year before. Revenue for fiscal 2025 was $36.75B.
Is AMGN profitable?
Yes. Amgen Inc. earned $9.39B in net income for the twelve months ended Sep 30, 2026, a net margin of 24.1%.
How much cash and debt does AMGN have?
Amgen Inc. reported $13.19B in cash and cash equivalents and $54.01B of debt on its most recent balance sheet in SEC filings.
How fast is AMGN revenue growing?
Amgen Inc.'s revenue changed +10.0% in fiscal 2025, to $36.75B. Its compound annual growth rate was +7.6% over 5 years and +5.4% over 10 years.
What is AMGN gross margin?
Amgen Inc.'s gross profit was $27.58B on $38.90B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 70.9%.
What is AMGN free cash flow?
Amgen Inc. generated $9.58B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $12.04B less capital expenditures.
What is AMGN earnings per share?
Diluted earnings per share were $17.24 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did AMGN last report financial results?
The latest statements here come from Amgen Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
Where does this AMGN financial data come from?
Quantisnow builds these statements from the structured XBRL data Amgen Inc. files with the SEC. It is provided for information only and is not investment advice.